**Natco Pharma Limited**
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

13th November, 2026

Corporate Relationship Department
M/s. BSE Ltd.
Mumbai 400 001
**Scrip Code: 524816**

Manager – Listing
M/s. National Stock Exchange of India Ltd
Mumbai 400 051
**Scrip Code: NATCOPHARM**

Dear Sir/Madam,

**Sub: -** Earnings Presentation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Earnings Presentation for the Q2 FY27.

Thanking you

Yours faithfully

For NATCO Pharma Limited

VENKAT RAMESH CHEKURI
Digitally signed by VENKAT RAMESH CHEKURI
Date: 2026.11.13 15:53:00 +05'30'

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl : as above



# NATCO Pharma Limited

## Earnings Presentation

**Q2 FY27**

# Disclaimer

THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE "COMPANY").

The material that follows is a Presentation of general background information about the Company's activities as at the date of the Presentation or as otherwise indicated. It is information given in summary form and does not purport to be complete and it cannot be guaranteed that such information is true and accurate. This Presentation has been prepared by and is the sole responsibility of the Company. By accessing this Presentation, you are agreeing to be bound by the trading restrictions. It is for general information purposes only and should not be considered as a recommendation that any investor should subscribe / purchase the Company shares.

This Presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward- looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Presentation and include statements regarding the Company's intentions, beliefs or current expectations concerning, amongst other things, its results or operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. There are some important factors that could cause material differences to Company's actual results. These include (i) our ability to successfully implement our strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological changes (v) investment and business income (vi) cash flow projections etc. (vii) exposure to market as well as other risks.

The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this Presentation, unless otherwise specified is only current as of the date of this Presentation. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements based on any subsequent development, information or events, or otherwise. Unless otherwise stated in this Presentation, the information contained herein is based on management information and estimates.

Any opinions expressed in this presentation are subject to change without notice. The presentation should not be construed as legal, tax, investment or other advice. None of the Company or any of its affiliates, advisers or representatives accepts any liability whatsoever for any loss howsoever arising from any information presented or contained in this presentation. The information contained in this presentation has not been independently verified. Furthermore, no person is authorized to give any information or make any representation which is not contained in, or is inconsistent with, this presentation. Any such extraneous or inconsistent information or representation, if given or made, should not be relied upon as having been authorized by or on behalf of the Company. Further, past performance is not necessarily indicative of future results.

This document is just a Presentation for information purposes and private circulation only and is not intended to be a "prospectus" or "offer document" or a "private placement offer letter" (as defined or referred to, as the case may be, under the Companies Act, 2013). It is clarified that this Presentation is not intended to be a document offering for subscription or sale of any securities or inviting offers from the Indian public (including any section thereof) or from persons residing in any other jurisdiction including the United States for the subscription to or sale of any securities including the equity shares of the Company or any of its subsidiaries. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of the Company's securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration there from.

This document has not been and will not be reviewed or approved by a regulatory authority in India or by any stock exchange in India. This presentation is confidential and this presentation or any part thereof should not be used or relied upon by any other party or for any other purpose and should not be copied, reproduced, recirculated, redistributed, published in any media, website or otherwise, in any form or manner, in part or as a whole, without the express consent in writing of the Company. Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited. The distribution of this presentation in certain jurisdictions may be restricted by law. Accordingly, any persons in possession of the aforesaid should inform themselves about and observe any such restrictions.


# Q2 FY27 - Key Business & Consolidated Financial Highlights


- Total Revenue for Q2FY27 stood at INR 10,194 Mn | International Formulations at INR 6,684 Mn | Domestic Formulations Revenue at 1,457 Mn
- Earnings Before Interest Tax Depreciation and Amortization (EBITDA)* stood at INR 3,100 Mn and EBITDA Margin at 30.4% for Q2FY27 as against 30.9% in Q1FY27
- Profit After Share of Profit of Associate for Q2FY27 stood at INR 2,026 Mn
- Earnings Per Share (EPS) for Q2FY27 stood at INR 11.31 per share
- During the quarter, NATCO acquired additional 13.25% stake in Adcock Ingram Holding Limited taking the total holdings to 49%. Profit Share From Our Associate Adcock Ingram Holdings Ltd for Q2FY27 Stood at INR 292 Mn
- Invested Additional US$ 16.7 million in eGenesis, Inc., NATCO's Total Investment in eGenesis amounts to US$ 24.7 million

*EBITDA and EBITDA Margin includes Other income

# ADCOCK INGRAM HOLDINGS

- Established in 1890 as a pharmacy in Krugersdorp, South Africa and evolved to be one of the biggest pharmaceutical and healthcare companies on the African continent.
- Second-largest South African based pharmaceutical company in terms of private market share.
- Engages in the manufacturing, selling & marketing and distribution of healthcare products to private and public sectors in Southern Africa.
- Southern Africa: Conducts business through four commercial divisions- Prescription, OTC, Hospital & Consumer.
- Owns 3 manufacturing facilities near Johannesburg, South Africa and 49% of an Indian JV that runs 2 manufacturing facilities in India.






**CLAYVILLE**
High volume oral liquids



**AEROTON**
Integrated steriles manufacture




















# Q2 FY27 – Segmental Performance

| Revenue Breakup (INR Mn) | Q2FY27 | Q2FY26 | Q1FY27 |
|---|---|---|---|
| **API Revenue** | 613 | 539 | 667 |
| **Pharmaceutical Formulation** | | | |
| Formulation – Domestic | 1,457 | 1,054 | 1,364 |
| International Formulations (Incl. profit share and subsidiaries) | 6,684 | 11,402 | 4,771 |
| **Pharmaceutical Formulations Total Revenue** | **8,141** | **12,456** | **6,135** |
| Crop Health Sciences | 610 | 524 | 408 |
| Other operating & non-operating income | 831 | 1,111 | 734 |
| **Consolidated Total Revenue** | **10,194** | **14,630** | **7,944** |

**Revenue Breakup (%) – Q2FY27**




**Revenue Breakup (%) – H1FY27**



# Consolidated Profit & Loss Statement

| Profit & Loss Statement (INR Mn) | Q2FY27 | Q2FY26 | Q1FY27 |
|---|---|---|---|
| **Total Revenue** | **10,194** | **14,630** | **7,944** |
| Total Expenses (before finance cost and depreciation) | 7,094 | 7,838 | 5,487 |
| **Earnings before interest, tax, depreciation and amortization (EBITDA)** | **3,100** | **6,792** | **2,457** |
| ***EBITDA margin* (%)*** | ***30.4%*** | ***46.4%*** | ***30.9%*** |
| Finance cost | 176 | 131 | 130 |
| Depreciation | 492 | 524 | 471 |
| Profit before tax (PBT) before exceptional items | 2,432 | 6,137 | 1,856 |
| Current and Deferred Tax | 698 | 958 | 634 |
| **Profit after tax (PAT) before share of profit of associate** | **1,734** | **5,179** | **1,222** |
| Share of profit of associate (net of tax) | 292 | - | 843 |
| **Profit after share of profit of associate** | **2,026** | **5,179** | **2,065** |
| Reported Earnings per share INR - Basic and Diluted | 11.31 | 28.94 | 11.53 |

**includes other income*

# Key Product Pipeline - USA

**29** **Para IVs in the pipeline**

**20+** **FTFs (including sole and shared**

## Key Sole FTFs (Para IV) in the pipeline

| Brand | Molecule | Therapeutic segment/ Primary Indication |
|---|---|---|
| **Kyprolis** | Carfilzomib (10mg) | Cancer/Multiple Myeloma |
| **Imbruvica** | Ibrutinib (tablet) | Cancer/Leukaemia |
| **Zydelig** | Idelalisib | Cancer/ Blood and Bone Marrow Cancer |
| **Lynparza** | Olaparib | Ovarian/Breast Cancer |
| **Ozempic** | Semaglutide pen 8mg/3ml & 2 mg/3ml) | Diabetes |
| **Balversa** | Erdafitinib | Bladder Cancer |
| **Wegovy** | Semaglutide (all strengths) | Weight Loss |
| **Tabrecta** | Capmatinib | Cancer/ Lung Cancer |

## Key Para IV products in the pipeline (Filing on NCE-1) date

| Brand | Molecule | Therapeutic segment/ Primary Indication |
|---|---|---|
| **Eliquis** | Apixaban | Anticogulant |
| **Ozempic** | Semaglutide pen (2 strengths) | Diabetes |
| **Lonsurf** | Trifluridine/Tipracil | Metastatic colorectal cancer |
| **Yondelis** | Trabectedin | Advanced soft-tissue sarcoma/ ovarian cancer |
| **Calquence** | Acalabrutinib | Cancer/Blood |
| **Kyprolis** | Carfilzomib 60 mg/ml | Cancer/Multiple Myeloma |
| **Nurtec** | Rimegepant | Migraine |
| **Jevtana** | Cabazitaxel | Cancer |
| **Everysdi** | Risdiplam Oral Solution | Spinal Muscular Atrophy |

*Data as on 30th September 2026*

# Our NCE | Cell & Gene Therapy Investments

## 1 eGenesis

- Invested US$ 24.7 million in a biotechnology company focused on xenotransplantation, by developing safe and effective human compatible organs for transplant
- First ever human transplant of a genetically engineered pig kidney was done in March'24
- 3 patients with end-stage kidney disease have received kidney xenotransplants; 2 patients achieved >8 months of dialysis independence
- FDA has cleared the Phase 1/2/3 clinical study for kidney xenotransplantation; initiation of 33-patient trial registration study to commence in early 2027
- FDA clearance received for Phase 1/2 clinical study for liver xenotransplantation in patients with acute-on-chronic liver failure (ACLF).

## 2 NRC - 2694

- NRC-2694-A is an orally administered small-molecule tyrosine kinase inhibitor discovered and developed by NATCO
- It is being tested for the treatment of Head and Neck cancer). A Phase 2 clinical trial for the treatment of Recurrent/Metastatic Head and Neck cancer who progressed on Keytruda® (Pembrolizumab manufactured by Merck & CO) has been approved by US FDA
- Currently, the patient recruitment is in progress, trial is being conducted in US and India.

## 3 Cellogen Therapeutics

- Invested US$ 2 million focused on advanced cellular engineering methods and gene-therapy-based approaches
- Developing Innovative third and fourth generation CAR-T cell therapies for leukemia and lymphoma genetic therapies for beta-thalassemia and sickle cell disease
- First human dosing for Leukemia will begin shortly in India
- Received GMP manufacturing approvals in India.

## 4 Stero Therapeutics

- Invested US$ 1 million with focus on developing novel therapy for metabolic diseases
- Focused on Cushing's syndrome with expansion into NASH
- Conducting pre-clinical animal studies.

# Earnings Call Details – Q2 FY27

**The Earnings call to discuss the operational and financial performance of the company with Mr. Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer, Mr. Amit Parekh, Chief Financial Officer, Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences and Mr. Rajeev Menon – Lead, Investor Relations are as below:**

**Details of the Earnings call:**

- *Date: 13th November 2026*
- *Time: 4.00 PM IST*
- *Pre-register link: Please Click Here to pre-register for the call*

# Thank You

## Contact:


**Rajeev Menon – Investor Relations**

r.menon@natcopharma.co.in / ir@natcopharma.co.in

**040-23546208/ Ext: 323**

**https://twitter.com/pharma_natco**

**https://www.linkedin.com/company/natcopharma**